FGF19 and neoplasm: As shown in Figure 8, inhibition of FGFR4/FGF19 autocrine axis enhances doxorubicin, but not cisplatin or paclitaxel, sensitivity in MDA-MB-468 and HCC1937 breast cancer cells, suggesting that the anti-FGF19 monoclonal antibody might potentiate sensitivity of refractory tumor cells to chemotherapy.